
Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results
Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with

Gilles Salles, University of Lyon
Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with rituximab for two years compared with those who did not.Gilles Sallesfrom the University of Lyon discussed his findings with Peter Goodwin during the 2010 European Hematology Association annual congress in Barcelona.
More from EHA 2010
All 2 interviewsThis is the last of the 2 EHA 2010 interviews. See them all.
Related Episodes

Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World
Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of t